KNSA — Kiniksa Pharmaceuticals International Share News
0.000.00%
Last trade - 00:00- $6.24bn
- $5.71bn
- $677.56m
Kiniksa Pharmaceuticals Ltd expected to post a loss of 7 cents a share - Earnings Preview
Brief: Kiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sjögren’s Disease
Brief: Kiniksa Pharmaceuticals Files For Mixed Shelf Of Up To $400 Million
Brief: Kiniksa Pharmaceuticals Unit Enters Master Services Agreement And Product Specific Agreement With Samsung Biologics
Expects Redomiciliation To Take Effect On Or Around June 27, 2024
U.S. STOCKS ON THE MOVE-Visa, Tesla, US energy sector
U.S. STOCKS ON THE MOVE-Neurocrine, SunPower, NextEra Energy
Kiniksa climbs after Q1 revenue beat
Kiniksa Pharmaceuticals Ltd reports results for the quarter ended in March - Earnings Summary
Brief: Kiniksa Pharmaceuticals Q1 EPS USD -0.25
Kiniksa Pharmaceuticals Ltd expected to post a loss of 16 cents a share - Earnings Preview
Brief: Kiniksa Pharmaceuticals Plans To Initiate A Phase 2b Trial With Abiprubart In Sjogren's Disease
Kiniksa Pharmaceuticals Ltd reports results for the quarter ended in September - Earnings Summary
Brief: Kiniksa Pharmaceuticals Q4 EPS USD 0.36
Kiniksa Pharmaceuticals Ltd expected to post a loss of 14 cents a share - Earnings Preview
Kiniksa Pharmaceuticals Ltd expected to post a loss of 14 cents a share - Earnings Preview
Brief: Kiniksa Pharmaceuticals Provides Corporate Update
Kiniksa Pharmaceuticals Ltd reports results for the quarter ended in September - Earnings Summary
Brief: Kiniksa Pharmaceuticals Ltd Says Cash Reserves Of $201 Million Expected To Fund Operations Into At Least 2027